Yen‐Shen Lu

Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine · 2019 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia et al. · New England Journal of Medicine · 2019 · 1K citations · Full text

Medicine, Oncology, Pharmacology +15

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Debu Tripathy, Seock‐Ah Im, Marco Colleoni et al. · The Lancet Oncology · 2018 · 1K citations

Medicine, Oncology, Pharmacology +16

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2020 · 609 citations · Full text

Medicine, Oncology, Pharmacology +15

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Fabrice André, Eva Ciruelos, Dejan Juric et al. · Annals of Oncology · 2020 · 599 citations · Full text

Medicine, Oncology, Pharmacology +17